Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues

M Menon, CE Tananis, LL Hicks… - The Journal of …, 1978 - Am Soc Clin Investig
M Menon, CE Tananis, LL Hicks, EF Hawkins, MG McLoughlin, PC Walsh
The Journal of Clinical Investigation, 1978Am Soc Clin Investig
The potent synthetic androgen methytrienolone (R 1881), which does not bind to serum
proteins, was utilized to characterize binding to receptors in human androgen responsive
tissues. Cytosol extracts prepared from hypertrophic prostates (BPH) were utilized as the
source of receptor for the initial studies. High affinity binding was detected in the cytosol of
29 of 30 samples of BPH (average number of binding sites, 45.8±4.7 fmol/mg of protein;
dissociation constant, 0.9±0.2 nM). This binding had the characteristics of a receptor: heat …
The potent synthetic androgen methytrienolone (R 1881), which does not bind to serum proteins, was utilized to characterize binding to receptors in human androgen responsive tissues. Cytosol extracts prepared from hypertrophic prostates (BPH) were utilized as the source of receptor for the initial studies. High affinity binding was detected in the cytosol of 29 of 30 samples of BPH (average number of binding sites, 45.8±4.7 fmol/mg of protein; dissociation constant, 0.9±0.2 nM). This binding had the characteristics of a receptor: heat lability, precipitability by 0-33% ammonium sulfate and by protamine sulfate, and 8S sedimentation coefficient. High affinity binding was also detected in cytosol prepared from seminal vesicle, epididymis, and genital skin but not in non-genital skin or muscle. However, similar binding was demonstrated in the cytosol of human uterus. The steroid specificities of binding to the cytosol of male tissues of accessory reproduction and of uterus were similar in that progestational agents were more effective competitors than natural androgens. Binding specificities in cytosol prepared from genital skin were distinctly different and were similar to those of ventral prostate from the castrated rat in that dihydrotestosterone was much more potent than progestins in competition. Thus binding of R 1881 to the cytosol of prostate, epididymis, and seminal vesicle has some characteristics of binding to a progesterone receptor.
When the nuclear extract from BPH was analyzed, high affinity binding was demonstrated that conformed to the specificities of binding to an androgen receptor. Here dihydrotestosterone was a more potent competitor than progestational agents. Similar patterns of binding were detected in the crude nuclear extracts from seminal vesicle, epididymis, and genital skin but not in uterus, muscle, or non-genital skin. We conclude that the androgen receptor is not demonstrable in the cytosol of prostate, epididymis, or seminal vesicle of non-castrated men but can be measured in the cytosol of genital skin and the nuclear extracts of androgen responsive tissues. Because steroid hormones exert their major influence within the nucleus of target tissues, the measurement of nuclear receptor may provide valuable insight into the regulation of growth of target tissues.
The Journal of Clinical Investigation